Opportunity Information: Apply for CDC RFA PS09 9130
Apply for CDC RFA PS09 9130
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Strengthening the Delivery and Quality of Sexually Transmitted Infections (STI) Prevention and Control Programs through Enhanced Laboratory Based STI Surveillance, Case Management and Program Evaluations in the Republic of South Africa" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.064 Laboratory Training, Evaluation, and Quality Assurance Programs.
- This funding opportunity was created on May 28, 2009 and posted on Apr 17, 2009.
- Applicants must submit their applications by Jun 30, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $300,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- The only applicant eligible to apply for these funds is the National Institute of Communicable Diseases, STI Reference Center for South Africa.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This CDC funding opportunity (CDC RFA PS09 9130) is a discretionary health grant offered as a cooperative agreement focused on improving sexually transmitted infection (STI) prevention and control in the Republic of South Africa. The central idea is that stronger STI programs also strengthen HIV prevention, since untreated or poorly managed STIs can increase HIV transmission risk and complicate broader sexual health outcomes. The announcement frames the work as a capacity-building effort for the National STI program, with the expectation that improvements at the national level will flow down to provincial, district, and municipal STI services.
The proposed approach emphasizes enhanced laboratory-based STI surveillance, stronger case management, and program evaluation. In practical terms, this signals a focus on making STI tracking more reliable through laboratory confirmation and better use of surveillance data, improving how STI cases are diagnosed and treated in real-world clinical settings, and assessing whether interventions are actually working. The inclusion of laboratory training, evaluation, and quality assurance (CFDA 93.064) indicates that laboratory systems and performance standards are a key part of the strategy, not just clinical guidelines. Overall, the opportunity is aimed at improving the quality and delivery of STI services by building systems that can detect trends, support timely and accurate diagnosis, and guide improvements based on evidence.
Funding is limited and targeted. CDC anticipated approximately 300,000 dollars in total funding to support about one award, although the published award parameters list a floor of 100,000 dollars and a ceiling of 1,000,000 dollars. There is no cost sharing or matching requirement. The program planned an estimated funding date prior to August 1, 2009, reflecting a relatively fast timeline between application and award for that funding cycle.
Eligibility is narrowly restricted: the only eligible applicant is the National Institute of Communicable Diseases (NICD), specifically the STI Reference Center for South Africa. This makes the announcement effectively a sole-eligible-applicant competition designed to fund a specific national technical institution with a defined role in STI reference services, surveillance support, and laboratory quality functions. The cooperative agreement mechanism also implies substantial involvement from CDC during implementation, such as technical collaboration, shared planning, and ongoing performance monitoring, rather than a hands-off grant.
Key administrative details include the posting date of April 17, 2009, a closing date of June 30, 2009 (unchanged), and an archive date of July 30, 2009. Questions about accessing the full announcement were directed to the CDC Procurement and Grants Office (PGO TIM) at 770-488-2700.
Frequently Asked Questions (FAQs)
What is the name and identifier of this funding opportunity?
This opportunity is a CDC funding opportunity identified as CDC RFA PS09-9130.
What type of grant is this?
It is a discretionary health grant offered as a cooperative agreement, meaning CDC is expected to have substantial involvement during implementation (for example, technical collaboration, shared planning, and ongoing performance monitoring).
What country and public health area does this opportunity focus on?
The work is focused on improving sexually transmitted infection (STI) prevention and control in the Republic of South Africa.
Why does the announcement connect STI work to HIV prevention?
The announcement is based on the idea that stronger STI programs also strengthen HIV prevention, because untreated or poorly managed STIs can increase HIV transmission risk and complicate broader sexual health outcomes.
What is the overall goal of the funded work?
The goal is to improve the quality and delivery of STI services by building stronger national STI program capacity, with the expectation that improvements at the national level will flow down to provincial, district, and municipal STI services.
What are the main programmatic focus areas described?
The described approach emphasizes: enhanced laboratory-based STI surveillance, stronger STI case management, and program evaluation.
What does "enhanced laboratory-based STI surveillance" mean in this context?
Based on the description provided, it signals a focus on making STI tracking more reliable through laboratory confirmation and better use of surveillance data to detect trends and guide improvements.
How is "case management" expected to be strengthened?
The announcement points to improving how STI cases are diagnosed and treated in real-world clinical settings, supported by better systems and data rather than relying only on clinical guidelines.
Why is program evaluation included as a core emphasis?
The opportunity highlights assessing whether interventions are working, with an evidence-based approach that uses evaluation results to guide improvements.
What role do laboratories play in this opportunity?
Laboratory systems and performance standards are described as a key part of the strategy. The inclusion of laboratory training, evaluation, and quality assurance (CFDA 93.064) indicates a strong emphasis on laboratory capacity and quality functions alongside surveillance and clinical improvements.
What is CFDA 93.064 and how is it referenced here?
The opportunity references CFDA 93.064 in connection with laboratory training, evaluation, and quality assurance, signaling that these laboratory-related activities are central to the strategy described.
How much funding is available under this opportunity?
CDC anticipated approximately $300,000 in total funding to support about one award. The published award parameters list a funding floor of $100,000 and a ceiling of $1,000,000.
How many awards does CDC expect to make?
The information provided indicates CDC anticipated about one award.
Is cost sharing or matching required?
No. The opportunity specifies there is no cost sharing or matching requirement.
What is the expected timing for the award?
The program planned an estimated funding date prior to August 1, 2009, indicating a relatively fast timeline between application and award for that funding cycle.
Who is eligible to apply?
Eligibility is narrowly restricted. The only eligible applicant is the National Institute of Communicable Diseases (NICD), specifically the STI Reference Center for South Africa.
Is this a competitive opportunity open to multiple organizations?
Based on the stated eligibility, it is effectively a sole-eligible-applicant competition designed to fund a specific national technical institution with a defined role in STI reference services, surveillance support, and laboratory quality functions.
What does a "cooperative agreement" imply for how CDC will work with the recipient?
As described, the cooperative agreement mechanism implies substantial CDC involvement during implementation, such as technical collaboration, shared planning, and ongoing performance monitoring, rather than a hands-off grant relationship.
When was the opportunity posted?
The posting date is April 17, 2009.
What was the application closing date?
The closing date was June 30, 2009, and it was listed as unchanged.
When was the opportunity archived?
The archive date is July 30, 2009.
Who should be contacted for questions about accessing the full announcement?
Questions about accessing the full announcement were directed to the CDC Procurement and Grants Office (PGO TIM) at 770-488-2700.
Browse more opportunities from the same category: Health
Next opportunity: Renal Function and Chronic Kidney Disease in Aging (R01)
Previous opportunity: Strengthening Graduate Public Health Training in the Republic of Mozambique under the President s Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS09 9130
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS09 9130) also looked into and applied for these:
| Funding Opportunity |
|---|
| Renal Function and Chronic Kidney Disease in Aging (R21) Apply for PA 09 166 Funding Number: PA 09 166 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Violence Against Women National On Line Resource Center and E Learning Community of Practice Apply for CDC RFA CE09 905 Funding Number: CDC RFA CE09 905 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $730,000 |
| MCH Autism Intervention Research Apply for HRSA 09 217 Funding Number: HRSA 09 217 Agency: Health Resources and Services Administration Category: Health Funding Amount: $400,000 |
| State Health Access Program (SHAP) Apply for HRSA 09 226 Funding Number: HRSA 09 226 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving Access to High Quality Comprehensive HIV related Services in Malawi through the Malawi Ministry of Health under the President s Emergency Plan for AIDS Relief Apply for CDC RFA PS09 967 Funding Number: CDC RFA PS09 967 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Human Immunodeficiency Virus (HIV) and Sexually Transmitted Diseases (STD) Partner Services Technical Assistance for Health Departments and their Grantees through Capacity Building Assistance Providers (CBA) Apply for CDC RFA PS09 9105 Funding Number: CDC RFA PS09 9105 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Outcome Monitoring of Mpowerment Delivered by Community Based Organizations Funded to Conduct HIV Prevention through CDC Funding Opportunity Announcement PS06 618 Apply for CDC RFA PS09 947 Funding Number: CDC RFA PS09 947 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Rapid Assessment Post Impact of Disaster (R03) Apply for PAR 09 171 Funding Number: PAR 09 171 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Rapid Assessment Post Impact of Disaster (R21) Apply for PAR 09 172 Funding Number: PAR 09 172 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| SSA Financial Literacy Research Consortium Apply for SSA ORP 09 1 Funding Number: SSA ORP 09 1 Agency: Office of Policy ORES Category: Health Funding Amount: $5,000,000 |
| Pilot Intervention and Services Research Grants (R34) Apply for PAR 09 173 Funding Number: PAR 09 173 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Health Research Program Apply for USAID M OAA GH HSR 09 919 Funding Number: USAID M OAA GH HSR 09 919 Agency: Agency for International Development Category: Health Funding Amount: $48,000,000 |
| Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research SBIR R43/R44 Apply for RFA AR 10 004 Funding Number: RFA AR 10 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Conference Support Program Apply for CDC PA GH09 902 Funding Number: CDC PA GH09 902 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Modeling the Scientific Workforce (U01) Apply for RFA GM 10 003 Funding Number: RFA GM 10 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Part D Coordinated HIV Services and Access to Research for Women, Infant, Children and Youth Apply for HRSA 09 221 Funding Number: HRSA 09 221 Agency: Health Resources and Services Administration Category: Health Funding Amount: $350,000 |
| Ancillary Studies to Large Ongoing Clinical Projects (R01) Apply for RFA AR 10 010 Funding Number: RFA AR 10 010 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Ancillary Studies to Large Ongoing Clinical Projects (R21) Apply for RFA AR 10 011 Funding Number: RFA AR 10 011 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Development of In Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR R41/R42) Apply for PA 09 178 Funding Number: PA 09 178 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of In Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (SBIR R43/R44) Apply for PA 09 179 Funding Number: PA 09 179 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS09 9130", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.